RayKnowChina Research Map
Shortlist

Nanning

People's Hospital of Guangxi Zhuang Autonomous Region

广西壮族自治区人民医院

Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at People's Hospital of Guangxi Zhuang Autonomous Region

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌21 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  3. Hepatocellular carcinoma肝细胞癌10 papers led
  4. Osteosarcoma骨肉瘤4 papers led
  5. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  6. Neuroblastoma神经母细胞瘤1 paper led
  7. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  8. Beta thalassaemiaβ 地中海贫血7 papers led
  9. Takayasu arteritis大动脉炎0 papers led
  10. IgA nephropathyIgA 肾病0 papers led

Not listed for: Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 21 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 3320212022: 7720222023: 4420232024: 1120242025: 552025

5 hospitals in Nanning for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  2. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  3. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  4. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

  5. Not yet recruiting
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764887

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan

  6. Not yet recruiting
    Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07918755

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteNanning, Zhongshan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueEBV & screening
Departments in papersENT / head & neck surgeryRadiation oncologyPathology / laboratory medicineMedical oncology
Papers it led21
  1. The Positive Feedback of lncRNA ANRIL/miRNA-339-5p/ZBTB7A Suppresses Metastasis of Nasopharyngeal Carcinoma Cells via SREBP1-FASN.2026Cancer scienceFree full text
  2. Hsa_circ_0000105 promotes nasopharyngeal carcinoma malignancy by miR-541-3p/S100A11 axis.2025Clinics (Sao Paulo, Brazil)Free full text
  3. Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China.2025ESMO openFree full text
  4. Machine learning-based prediction of nasopharyngeal carcinoma risk: a clinical approach.2025Frontiers in immunologyFree full text
  5. Long-term immune checkpoint inhibitor therapy in a patient with metastatic nasopharyngeal carcinoma: a case report.2025Frontiers in immunologyFree full text
  6. Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region.2025PloS oneFree full text
  7. Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy.2024Human vaccines & immunotherapeuticsFree full text
  8. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of nasopharyngeal carcinoma with cervical lymph node metastasis.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  9. Nutritional intervention for the prognosis of nasopharyngeal carcinoma chemoradiotherapy patients: A meta-analysis.2023MedicineFree full text
  10. Blood biomarkers in the application of diagnosis and prediction of overall survival for 1089 patients with nasopharyngeal carcinoma.2023Scientific reportsFree full text
  11. Interobserver Variations in Target Delineation in Intensity-Modulated Radiation Therapy for Nasopharyngeal Carcinoma and its Impact on Target Dose Coverage.2023Technology in cancer research & treatmentFree full text
  12. miR-3942-3p Increases the radiosensitivity of nasopharyngeal carcinoma through negatively regulating BARD1.2022Acta biochimica Polonica
  13. LINC00324 suppresses apoptosis and autophagy in nasopharyngeal carcinoma through upregulation of PAD4 and activation of the PI3K/AKT signaling pathway.2022Cell biology and toxicology
  14. Prognostic value of hypothyroidism in patients undergoing intensity-modulated radiation therapy for nasopharyngeal carcinoma.2022Head & neck
  15. STAT3 regulates SRGN and promotes metastasis of nasopharyngeal carcinoma through the FoxO1-miR-148a-5p-CREB1 axis.2022Laboratory investigation; a journal of technical methods and pathology
  16. CircMAN1A2 promotes vasculogenic mimicry of nasopharyngeal carcinoma cells through upregulating ERBB2 via sponging miR-940.2022Oncology researchFree full text
  17. Regulatory Mechanism of lncRNA CTBP1-AS2 in Nasopharyngeal Carcinoma Cell Proliferation and Apoptosis via the miR-140-5p/BMP2 Axis.2022Protein and peptide letters
  18. A Four-Gene Signature Model Improves the Prediction of Distant Metastasis in Patients with Nasopharyngeal Carcinoma: A Retrospective, Three-Center Observational Study.2022Technology in cancer research & treatmentFree full text
  19. LINC00641 contributes to nasopharyngeal carcinoma cell malignancy through FOXD1 upregulation at the post-transcriptional level.2021Biochemistry and cell biology = Biochimie et biologie cellulaire
  20. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase.2021BioengineeredFree full text
  21. PAD4 inhibitor promotes DNA damage and radiosensitivity of nasopharyngeal carcinoma cells.2021Environmental toxicology
Chinese-language papers (not in the count)2
  1. [Effect of endoscopic surgery combined with chemotherapy and radiotherapy on prognosis of early nasopharyngeal carcinoma patients in high incidence area].2024Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
  2. [Diagnosis of nasopharyngeal carcinoma with convolutional neural network on narrowband imaging].2023Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
All its trials on ClinicalTrials.gov, any status15
  1. Impacted Tooth Management and Osteoradionecrosis Risk in NPCNot yet recruitingNCT07764887Study siteN/AStart 2026-08
  2. Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic FeaturesNot yet recruitingNCT07918755Study siteStart 2026-11
  3. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  4. Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Study sitePhase 3Start 2024-06
  5. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPCRecruitingNCT06235203Study sitePhase 3Start 2024-07
  6. Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Study siteN/AStart 2017-10
  7. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  8. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Study sitePhase 2Start 2022-05
  9. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  10. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  11. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05011227Study sitePhase 2Start 2021-08
  12. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  13. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
  14. Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02250599Study sitePhase 2Start 2014-08
  15. Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT00778908Study sitePhase 2/Phase 3Start 2008-01
More papers found outside PubMed (not counted)17
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  4. 889P Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A prospective, single-arm, phase II trial2024Annals of Oncologyarticle
  5. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  6. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncologyconference-abstract
  7. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncologyarticle
  8. CSF-1R promotes vasculogenic mimicry via epithelial-mesenchymal transition in nasopharyngeal carcinoma cells2023ONCOLOGIEarticle
  9. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  10. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  11. Additional file 2 of Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy2022Figsharedataset
  12. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncologyconference-abstract
  13. ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma2022Biocellarticle
  14. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  15. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract
  16. KIF15 Accelerated The Progression of Nasopharyngeal Carcinoma and Predict Poor Prognosis2021Research Squarepreprint
  17. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 002025

4 hospitals in Nanning for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyMolecular markers & genomics
Departments in papersPathology / laboratory medicineClinical trials / research unit

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 10 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
10
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 552025

4 hospitals in Nanning for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicine
Papers it led10
  1. Syntaxin-7 promotes EMT and tumor progression via NF-κB signaling and is associated with macrophage infiltration: pan-cancer analysis and experimental validation in hepatocellular carcinoma.2025BMC cancerFree full text
  2. TBA-MLR score: a metabolic-immune prognostic biomarker for postoperative hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  3. Hyaluronic acid coated GSH-responsive Mn(III)-pMOF-based nanosonosensitizers for cascade-catalytic enhancement of sonodynamic therapy against hepatocellular carcinoma.2025International journal of biological macromolecules
  4. Up-regulation of blood-circulating TIM-4-expressing monocytes and potential diagnostic biomarker sTIM-4 in primary liver cancer.2025Scientific reportsFree full text
  5. The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study.2025Scientific reportsFree full text
  6. ADH4-a potential prognostic marker for hepatocellular carcinoma with possible immune-related implications.2024BMC cancerFree full text
  7. Preoperative albumin-alkaline phosphatase ratio affects the prognosis of patients undergoing hepatocellular carcinoma surgery.2024Cancer biomarkers : section A of Disease markersFree full text
  8. Machine learning-based integration develops a neutrophil-derived signature for improving outcomes in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  9. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.2022Cancer
  10. Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide in vitro and in vivo.2021Drug deliveryFree full text
Chinese-language papers (not in the count)2
  1. [Angiopoietin-2 regulates vessels encapsulated by tumor clusters positive hepatocellular carcinoma nest-type metastasis via integrin α5β1].2021Zhonghua yi xue za zhi
  2. [Relationship of operation manner and postoperative recurrence of hepatocellular carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status3
  1. Anlotinib for Hepatocellular CarcinomaStatus unknownNCT04954521Lead sponsorStart 2021-06
  2. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  3. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Study sitePhase 2Start 2023-10

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 002025

10 hospitals in Nanning for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Nanning for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Nanning for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

1 hospital in Nanning for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  2. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 7 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 2.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 332025

6 hospitals in Nanning for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led7
  1. A direct multiplex isothermal amplification-reverse dot blot hybridization system for β-thalassemia diagnosis.2025Annals of hematology
  2. A sample-in- result -out microfluidic system for β-thalassemia diagnostics via direct whole blood PCR-reverse dot blot.2025Clinica chimica acta; international journal of clinical chemistry
  3. The 1357 bp deletion in β-thalassemia: molecular profiling and hematological characterization in a Guangxi cohort.2025Molecular biology reports
  4. Misdiagnosis of β-Thalassemia Major Due to Chinese Gγ+(Aγδβ)0-Thalassemia Combined with β0-Thalassemia.2024Hemoglobin
  5. Clinical experience using peripheral blood parameters to analyse the mutation type of thalassemia carriers in pregnant women.2023Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  6. Detection of hemoglobin H disease by long molecule sequencing.2022Journal of clinical laboratory analysis
  7. Compound heterozygotes of Hb Constant Spring and Hb Stanleyville II in HbE/β0-thalassemia.2021Clinical chemistry and laboratory medicine
Chinese-language papers (not in the count)1
  1. [Genotype and Phenotype of α-Thalassemia Fusion Gene in Huadu District of Guangzhou, Guangdong Province of China].2023Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)4
  1. Detection of a Hb A2 -Melbourne (HBD: c.130G>A) combined with β-thalassemia in a Chinese individual.2020Journal of clinical laboratory analysis
  2. Prenatal Diagnosis of β-thalassemia with Cell-free Fetal DNA in Maternal Plasma.2019Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  3. A novel compound heterozygosity in Southern China: IVS-II-5 (G > C) and IVS-II-672 (A > C).2016Hemoglobin
  4. Hb Matera (HBB: c.167 T > A): A Second Case Detected in a Pregnant Chinese Woman by the Capillary Electrophoresis Method.2016Hemoglobin

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanning for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanning for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Combined Acoustic Radiation Force Impulse and Conventional Ultrasound in the Quantitative Assessment of Immunoglobulin a Nephropathy.2019Ultrasound in medicine & biology
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广西壮族自治区人民医院

People's Hospital of Guangxi Zhuang Autonomous Region

南宁

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Affiliated Liuzhou People's Hospital of Guangxi Medical University; Sciences & the People's Hospital of Guangxi Zhuang Autonomous Region; Fusui County People's Hospital of Guangxi; Liuzhou People's Hospital of Guangxi; People's Hospital of Guangxi Hezhou; People's Hospital of Guangxi Zhuang Autonomous Regiocnning; Third People's Hospital of Guangxi Zhuang Autonomous Region; The People's Hospital of Guangxi Zhuang Autonomous Region

Suggest a correctionDownload the data